AbCellera Biologics Inc.
ABCL
$10.97
$0.625.94%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -51.29% | -81.46% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -51.29% | -81.46% | |||
| Cost of Revenue | -1.45% | -6.85% | |||
| Gross Profit | -9.36% | -631.81% | |||
| SG&A Expenses | 12.29% | -28.37% | |||
| Depreciation & Amortization | 2.22% | 11.68% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.51% | -10.35% | |||
| Operating Income | -9.14% | -101.24% | |||
| Income Before Tax | -19.03% | -154.05% | |||
| Income Tax Expenses | 44.48% | 39.62% | |||
| Earnings from Continuing Operations | -28.41% | -382.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.41% | -382.56% | |||
| EBIT | -9.14% | -101.24% | |||
| EBITDA | -10.07% | -125.66% | |||
| EPS Basic | -27.39% | -377.85% | |||
| Normalized Basic EPS | -18.00% | -139.34% | |||
| EPS Diluted | -27.39% | -368.42% | |||
| Normalized Diluted EPS | -18.00% | -139.34% | |||
| Average Basic Shares Outstanding | 0.82% | 1.12% | |||
| Average Diluted Shares Outstanding | 0.82% | 1.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||